Heavy immunotherapy drug Tai Sanqi ® China to break through 30 years of treatment for small cell lung cancer

on April 29, , Roche's cancer immunoinnovation drug Tesanchi ® ("Tecentriq®, generic name: Atlizumab) combined chemotherapy for first-line treatment of wide-term small cell lung cancer was officially launched in China, which is the first indication approved and listed in China by the Tethan Qi ® On February 13 this year, China's State Drug Administration officially approved The Tai Sanqi ® for first-line treatment of a wide range of small cell lung cancer, marking Roche in China officially entered the field of tumor immunotherapy, China's small cell lung cancer patients no longer have no medicine, breaking the 30-year "drug shortage" dilemma Te Sanqi ® (Tecentriq®, generic name: Atalizumab) combined chemotherapy is the world's first, and China is currently the only approved for first-line treatment of a wide range of small cell lung cancer tumor immunotherapy is also® the first innovative drug in more than 30 years to be shown to benefit significantly from small cell lung cancer patients clinical needs are urgent, patients' survival needs to improve
malignant tumor has become a serious threat to the health of Chinese group of major public health problems According to the 2017 "China's Current Situation and Trends" report, lung cancer has been the first incidence of malignant tumors in China for 16 consecutive years, in 2015 China's lung cancer death toll of about 631,000 cases, the mortality rate of 45.87 per 100,000 In recent years, the incidence of lung cancer is increasing year by year, and shows the trend of youth lung cancer according to the pathological type, can be divided into non-small cell lung cancer and small cell lung cancer, of which small cell lung cancer accounts for about 15% of lung cancer, is a strong aggressive, rapid proliferation of malignant tumors The prognosis of patients with small cell lung cancer is very poor, and two-thirds of patients have reached a wide range of time at the time of initial diagnosis, that is, the disease has been found at the time of the distant organ or lymph node metastasis, after diagnosis, the average survival rate of 5 years after diagnosis is only 2% Vice Chairman of the Chinese Society of Clinical Oncology (CSCO), CSCO Small Cell Lung Cancer Professional Committee, Jilin Province Cancer Hospital Professor Cheng Ying introduced: "Small cell lung cancer is the most invasive lung cancer subtype, rapid, when patients have breathing difficulties and persistent cough and other symptoms before thinking of medical treatment, often there has been metastasis." Etoposide combined platinum chemotherapy is still a wide range of small cell lung cancer first-line treatment of the standard program has been more than 30 years, although most patients received initial treatment after the relief, but quickly relapsed drug resistance, and after recurrence lack of effective treatment, so the survival rate of broad-based small cell lung cancer is very low for 5 years "
innovative immunotherapy "break the ground" for patients to bring greater benefits
Tai Sanqi ® (Atalizumab) combined chemotherapy for first-line treatment of a wide range of small cell lung cancer approved market, mainly based on the global multi-center phase III clinical trial IMpower133 trial results The trial was conducted in a group of 403 patients with a wide range of small cell lung, randomly divided into two groups, compared to the combination of Tethachi® (Atalizumab) combined chemotherapy, with single chemotherapy to treat the efficacy and safety of small cell lung cancer study showed that the combined chemotherapy® group of the Tetha®aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa In 13.9-month follow-up, it was found that the proportion of patients with continuous remission of the disease in the experimental group was three times higher than that of the chemotherapy group (15% v 5%), and in the longer follow-up, the combined chemotherapy group of The san chi ® (attili-zuma) was treated, with 1/3 of the patients surviving for more than 18 months, with a significant increase of 21% compared to the 21% in the chemotherapy group In terms of safety, the performance of the Tesan Chi ® combined chemotherapy group was consistent with the safety of the ® Professor Cheng Ying, of the , said: The IMpower133 study is the first Phase III study in which immunotherapy has been positive for the first line of treatment for small cell lung cancer in a wide range of periods, and 100 patients have been contributed to this study Studies have shown that the median survival of the Tesan chi ® combined chemotherapy group reached 12.3 months, and compared with standard chemotherapy, the combined chemotherapy of Tai Sanqi ® combined chemotherapy can significantly prolong the total survival of patients with wide-term small cell lung cancer and reduce the risk of death The IMpower133 study is the first phase III study in 30 years to achieve a median improvement in the systematic treatment of patients with wide-ranging small cell lung cancer, a milestone in the first-line treatment of wide-term small cell lung cancer, a new first-line treatment standard for wide-term small cell, and the listing of Tai Shengqi ® means that China's small cell lung cancer has officially entered a new era of immunity The tae-Sanchi ® is an innovative monoclonal antibody developed by Roche for tumor immunotherapy Unlike the tumor immunotherapy specifically for PD1, the Tesan qi ® by binding with the PD-L1 protein on the surface of tumor cells and the surface of tumor-soaked immune cells, not only can prevent PD-L1 from binding to PD-1 receptors, but also prevent PD-L1 and B7.1 receptors from binding, helping the body to identify tumor cells, but also further activate the body's immune system T-cell attack tumor cells with the launch of Tai Sanqi ® in China, marks Roche's full coverage in the field of lung cancer treatment in China, providing a comprehensive choice of lung cancer personalized treatment for the vast number of lung cancer patients in China: Treatment of EGFR gene mutation non-small cell lung cancer drug Trokai ® (generic name: hydrochloric acid elotini) anti-angiogenesis drug Anvetin ® (generic name: Beibei zhuad) treatment alkaloid Positive local late-stage or metastatic non-small cell lung cancer drug Ansansa ® (generic name: Aletini) the tumor immunoinnovation drug Tai Sanqi ® (generic name: Atalizumab) for a wide range of small cell lung cancer in addition, Roche is also conducting phase III clinical studies on rare targets of lung cancer such as NTRK, ROS1, to further promote the physical treatment of lung cancer